The ERBB network facilitates KRAS-driven lung tumorigenesis
Open accessPublished version of a preprint
Abstract
Abstract KRAS is the most frequently mutated driver oncogene in human adenocarcinoma of the lung. There are presently no clinically proven strategies for treatment of KRAS-driven lung cancer. Activating mutations in KRAS are thought to confer independence from upstream signaling, however recent data suggest that this independence may not be absolute. Here we show that initiation and progression of KRAS-driven lung tumors requires input from ERBB family RTKs: Multiple ERBB RTKs are expressed and active from the earliest stages of KRAS driven lung tumor development, and treatment with a multi-ERBB inhibitor suppresses formation of KRas G12D -driven lung tumors. We present evidence that ERBB activity amplifies signaling through the core RAS pathway, supporting proliferation of KRAS mutant tumor cells in culture and progression to invasive disease in vivo . Importantly, brief pharmacological inhibition of the ERBB network significantly enhances the therapeutic benefit of MEK inhibition in an autochthonous tumor setting. Our data suggest that lung cancer patients with KRAS-driven disease may benefit from inclusion of multi-ERBB inhibitors in rationally designed treatment strategies. One Sentence Summary G12 Mutant KRAS requires tonic ERBB network activity for initiation and maintenance of lung cancer
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Pan-ERBB inhibition enhanced the potency of MEK inhibition in vitro and in vivo.
“Indeed, pan-ERBB inhibition enhanced the potency of MEK inhibition in vitro and in vivo.”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [61]
ERBB activity establishes a feed-forward loop to amplify signaling through the core RAS-ERK cascade to sustain survival and proliferation in KRAS-mutant NSCLC.
“ERBB activity establishes a feed-forward loop to amplify signaling through the core RAS-ERK cascade to sustain survival and proliferation in KRAS-mutant NSCLC.”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [61]
In Kruspig et al., multiple ERBB ligands and receptors were highly expressed in a KRASG12D mouse model.
“multiple ERBB ligands (e.g., Areg, Ereg, Nrg3, Nrg4, and Hbegf) and receptors (for example, Erbb2 and Erbb3) were highly expressed in a KRASG12D mouse model.”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · see citing works
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400 · see citing works
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364 · see citing works
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160 · see citing works
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668 · see citing works
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732 · see citing works
Allemani, C., Weir, H. K., Carreira, H., Harewood, R., Spika, D., Wang, X.-S., Bannon, F., Ahn, J. V., Johnson, C. J., Bonaventure, A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62038-9 · Cited by 2,614 · see citing works
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · see citing works
Bhattacharjee, A., Richards, W. G., Staunton, J. E., Li, C., Monti, S., Vasa, P. P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M. A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191502998 · Cited by 2,540 · see citing works
EGF–ERBB signalling: towards the systems level
Citri, A., & Yarden, Y. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1962 · Cited by 2,004 · see citing works
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-rasPreprint
Jackson, E. L., Willis, N. A., Mercer, K. L., Bronson, R. T., Crowley, D. G., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,877 · see citing works
Multiple Ras-dependent phosphorylation pathways regulate Myc protein stabilityPreprint
Sears, R. C., Nuckolls, F., Haura, E. B., Taya, Y., Tamai, K., & Nevins, J. R. (2000) · Genes & Development · doi:10.1101/gad.836800 · Cited by 1,379 · see citing works
The ErbB/HER family of protein-tyrosine kinases and cancer
Roskoski, R. J. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,365 · see citing works
Diversity of gene expression in adenocarcinoma of the lung
Garber, M. E., Troyanskaya, O. G., Schlüns, K., Petersen, S., Thäsler, Z., Pacyna-Gengelbach, M., van de Rijn, M., Rosen, G., Perou, C. M., Whyte, R. I., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241500798 · Cited by 1,301 · see citing works
Okayama, H., Kohno, T., Ishii, Y., Shimada, Y., Shiraishi, K., Iwakawa, R., Furuta, K., Tsuta, K., Shibata, T., Yamamoto, S., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1403 · Cited by 881 · see citing works
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691 · see citing works
Zhu, C.-Q., da Cunha Santos, G., Ding, K., Sakurada, A., Cutz, J.-C., Liu, N., Zhang, T., Marrano, P., Whitehead, M., Squire, J. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8924 · Cited by 661 · see citing works
Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.
Press, M. F., Cordon‐Cardo, C., & Slamon, D. J. (1990) · PubMed · Cited by 643 · see citing works
Modernizing Reference Genome Assemblies
Church, D., Schneider, V. A., Graves, T., Auger, K., Cunningham, F., Bouk, N., Chen, H.-C., Agarwala, R., McLaren, W., Ritchie, G., et al. (2011) · PLoS Biology · doi:10.1371/journal.pbio.1001091 · Cited by 563 · see citing works
EGF Receptor is Required for KRAS-induced Pancreatic Tumorigenesis
Ardito, C. M., Grüner, B., Takeuchi, K. K., Lubeseder-Martellato, C., Teichmann, N., Mazur, P., DelGiorno, K. E., Carpenter, E. S., Halbrook, C., Hall, J. C., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.07.024 · Cited by 522 · see citing works
Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis
Sarkisian, C. J., Keister, B. A., Stairs, D. B., Boxer, R. B., Moody, S. E., & Chodosh, L. A. (2007) · Nature Cell Biology · doi:10.1038/ncb1567 · Cited by 490 · see citing works
Targeting the ERBB family in cancer: couples therapy
Tebbutt, N. C., Pedersen, M. W., & Johns, T. G. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3559 · Cited by 464 · see citing works
Distinct Thresholds Govern Myc's Biological Output In Vivo
Murphy, D. J., Junttila, M. R., Pouyet, L., Karnezis, A., Shchors, K., Bui, D. A., Brown-Swigart, L., Johnson, L., & Evan, G. I. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.10.018 · Cited by 456 · see citing works
Self-citationEGF Receptor Signaling Is Essential for K-Ras Oncogene-Driven Pancreatic Ductal Adenocarcinoma
Navas, C., Hernández-Porras, I., Schuhmacher, A. J., Sibilia, M., Guerra, C., & Barbacid, M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.001 · Cited by 391 · see citing works
Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities
Kerr, E. M., Gaude, E., Turrell, F. K., Frezza, C., & Martins, C. P. (2016) · Nature · doi:10.1038/nature16967 · Cited by 308 · see citing works
Self-citationSun, C., Hobor, S., Bertotti, A., Zecchin, D., Huang, S., Galimi, F., Cottino, F., Prahallad, A., Grernrum, W., Tzani, A., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.045 · Cited by 304 · see citing works
Stage-specific sensitivity to p53 restoration during lung cancer progression
Feldser, D. M., Kostova, K. K., Winslow, M. M., Taylor, S. E., Cashman, C., Whittaker, C. A., Rivera, F. J. S., Resnick, R., Bronson, R. T., Hemann, M. T., et al. (2010) · Nature · doi:10.1038/nature09535 · Cited by 271 · see citing works
Selective activation of p53-mediated tumour suppression in high-grade tumours
Junttila, M. R., Karnezis, A. N., Garcia, D. A., Madriles, F., Kortlever, R. M., Rostker, F., Swigart, L. B., Pham, D. M., Seo, Y., Evan, G. I., et al. (2010) · Nature · doi:10.1038/nature09526 · Cited by 244 · see citing works
Self-citationReduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer
de Bruin, E. C., Cowell, C., Warne, P. H., Jiang, M. Z., Saunders, R. E., Melnick, M. A., Gettinger, S. N., Walther, Z., Wurtz, A., Heynen, G. J. J. E., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0741 · Cited by 200 · see citing works
Expression of the c-erbB-3 protein in normal human adult and fetal tissues.
Prigent, S. A., Lemoine, N. R., Hughes, C., Plowman, G. D., Selden, C., & Gullick, W. (1992) · PubMed · Cited by 182 · see citing works
Molina-Arcas, M., Hancock, D. C., Sheridan, C., Kumar, M. S., & Downward, J. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0446 · Cited by 157 · see citing works
Grabocka, E., Pylayeva‐Gupta, Y., Jones, M. V., Lubkov, V., Yemanaberhan, E., Taylor, L. J., Jeng, H. H., & Bar‐Sagi, D. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.005 · Cited by 141 · see citing works
LAMC2 enhances the metastatic potential of lung adenocarcinoma
Moon, Y. W., Rao, G., Kim, J., Shim, H. S., Park, K.-S., An, S. S., Kim, B. J., Steeg, P. S., Sarfaraz, S., Lee, L. C., et al. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2014.228 · Cited by 130 · see citing works
Afatinib restrains K-RAS–driven lung tumorigenesis
Moll, H. P., Pranz, K., Musteanu, M., Grabner, B., Hruschka, N., Mohrherr, J., Aigner, P., Stiedl, P., Brcic, L., Laszlo, V., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao2301 · Cited by 125 · see citing works
Zhang, J., Iwanaga, K., Choi, K. C., Wislez, M., Raso, M. G., Wei, W., Wistuba, I. I., & Kurie, J. M. (2008) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0014 · Cited by 73 · see citing works
Sunaga, N., Kaira, K., Imai, H., Shimizu, K., 中野, 哲., Shames, D. S., Girard, L., Soh, J., Sato, M., Iwasaki, Y., et al. (2012) · Oncogene · doi:10.1038/onc.2012.402 · Cited by 67 · see citing works
Powell, C. A., Nasser, M. W., Zhao, H., Wochna, J. C., Zhang, X., Shapiro, C. L., Shilo, K., & Ganju, R. K. (2015) · Oncotarget · doi:10.18632/oncotarget.3442 · Cited by 63 · see citing works
Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies
Waters, A. M., Ozkan‐Dagliyan, I., Vaseva, A. V., Fer, N. D., Strathern, L. A., Hobbs, G. A., Tessier‐Cloutier, B., Gillette, W., Bagni, R., Whiteley, G., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aao3332 · Cited by 61 · see citing works
Gollamudi, M., Nethery, D. E., Liu, J., & Kern, J. A. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2003.08.027 · Cited by 55 · see citing works
Sánchez‐Martín, M., & Pandiella, A. (2011) · International Journal of Cancer · doi:10.1002/ijc.26358 · Cited by 52 · see citing works
Cytokeratin19 induced by HER2/ERK binds and stabilizes HER2 on cell membranes
Ju, J.-H., Oh, S., Lee, K.-M., Yang, W. S., Nam, K. S., Moon, H.-G., Noh, D., Kim, C. G., Park, G. B., Park, J. B., et al. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.155 · Cited by 50 · see citing works
Irreversible Multitargeted ErbB Family Inhibitors for Therapy of Lung and Breast Cancer
Subramaniam, D. S., He, A. R., Hwang, J., Deeken, J. F., Pishvaian, M. J., Hartley, M. L., & Marshall, J. L. (2015) · Current Cancer Drug Targets · doi:10.2174/1568009614666141111104643 · Cited by 36 · see citing works
Cicchini, M., Buza, E. L., Sagal, K. M., Gudiel, A. A., Durham, A. C., & Feldser, D. M. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.01.069 · Cited by 35 · see citing works
Hock, A. K., Cheung, E. C., Humpton, T. J., Monteverde, T., Paulus-Hock, V., Lee, P., McGhee, E. J., Scopelliti, A., Murphy, D. J., Strathdee, D., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01741-0 · Cited by 24 · see citing works
Self-citationADAM proteases, ErbB pathways and cancer
Zhou, B. S., Fridman, J. S., Liu, X., Friedman, S., Newton, R. C., & Scherle, P. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.6.591 · Cited by 23 · see citing works
Kamata, T., Giblett, S. M., & Pritchard, C. A. (2017) · Blood · doi:10.1182/blood-2017-02-770149 · Cited by 17 · see citing works
Chen, H., Liu, C.-H., Chang, Y.-H., Yu, S., Ho, B., Hsu, C., Yang, T., Chen, K., Hsu, K.-H., Tseng, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7029 · Cited by 15 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
RAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103 · see citing works
EGFR signaling pathway as therapeutic target in human cancers
Levantini, E., Maroni, G., Re, M. D., & Tenen, D. G. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.04.002 · Cited by 372 · see citing works
Muthalagu, N., Monteverde, T., Raffo-Iraolagoitia, X., Wiesheu, R., Whyte, D., Hedley, A., Laing, S., Kruspig, B., Upstill-Goddard, R., Shaw, R., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0620 · Cited by 182 · see citing works
Self-citationKRAS <sup>G12C</sup> inhibition produces a driver-limited state revealing collateral dependencies
Lou, K., Steri, V., Ge, A. Y., Hwang, Y. C., Yogodzinski, C. H., Shkedi, A. R., Choi, A. L. M., Mitchell, D. C., Swaney, D. L., Hann, B., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aaw9450 · Cited by 175 · see citing works
Dost, A. F. M., Moye, A. L., Vedaie, M., Tran, L. M., Fung, E., Heinze, D. M., Villacorta-Martín, C., Huang, J., Hekman, R. M., Kwan, J., et al. (2020) · Cell stem cell · doi:10.1016/j.stem.2020.07.022 · Cited by 160 · see citing works
Xiang, Y., Liu, X., Wang, Y., Zheng, D., Meng, Q., Jiang, L., Yang, S., Zhang, S., Zhang, X., Liu, Y., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1366260 · Cited by 146 · see citing works
Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future
Uras, I. Z., Moll, H. P., & Casanova, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124325 · Cited by 134 · see citing works
New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
Yang, H., Liang, S.-Q., Schmid, R. A., & Peng, R.-W. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00953 · Cited by 129 · see citing works
Afatinib restrains K-RAS–driven lung tumorigenesis
Moll, H. P., Pranz, K., Musteanu, M., Grabner, B., Hruschka, N., Mohrherr, J., Aigner, P., Stiedl, P., Brcic, L., Laszlo, V., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao2301 · Cited by 125 · see citing works
TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target
Yu, J., Zhou, D., Yang, X., Cui, B., Tan, F., Wang, J., Li, K., Shang, S., Zhang, C., Lv, X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17385-0 · Cited by 116 · see citing works
Kubli, S. P., Bassi, C., Roux, C., Wakeham, A. C., Göbl, C., Zhou, W., Jafari, S. M., Snow, B. E., Jones, L., Palomero, L., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1815126116 · Cited by 112 · see citing works
Cell Type–Specific Adaptive Signaling Responses to KRASG12C Inhibition
Solanki, H. S., Welsh, E. A., Fang, B., Izumi, V., Darville, L., Stone, B., Franzese, R., Chavan, S., Kinose, F., Imbody, D., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3872 · Cited by 106 · see citing works
Knight, J. R. P., Alexandrou, C., Skalka, G. L., Vlahov, N., Pennel, K., Officer, L., Teodosio, A., Kanellos, G., Gay, D. M., May-Wilson, S., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0652 · Cited by 96 · see citing works
MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma
Maddipati, R., Norgard, R. J., Baslan, T., Rathi, K. S., Zhang, A. X. W., Saeid, A., Higashihara, T., Wu, F., Kumar, A., Annamalai, V., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1826 · Cited by 95 · see citing works
Gong, K., Guo, G., Panchani, N., Bender, M. E., Gerber, D. E., Minna, J. D., Fattah, F., Gao, B., Peyton, M., Kernstine, K., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0048-0 · Cited by 92 · see citing works
Dent, P., Booth, L. A., Roberts, J. L., Liu, J., Poklepovic, A. S., Lalani, A. S., Tuveson, D. A., Martinez, J., & Hancock, J. F. (2019) · Oncogene · doi:10.1038/s41388-019-0849-8 · Cited by 80 · see citing works
Santarpia, M., Ciappina, G., Spagnolo, C. C., Squeri, A., Passalacqua, M. I., Aguilar, A., Gonzalez-Cao, M., Giovannetti, E., Silvestris, N., & Rosell, R. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-639 · Cited by 65 · see citing works
Ponz‐Sarvisé, M., Corbo, V., Tiriac, H., Engle, D. D., Frese, K. K., Oni, T. E., Hwang, C., Öhlund, D., Chio, I. I. C., Baker, L. A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1398 · Cited by 63 · see citing works
Arif, A., Alameri, A. A., Tariq, U. B., Ansari, S. A., Sakr, H. I., Qasim, M. T., Al-joborae, F. F. M., Ramírez‐Coronel, A. A., Jabbar, H. S., Gabr, G. A., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109581 · Cited by 61 · see citing works
Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers
Kobayashi, Y., Chhoeu, C., Li, J., Price, K. S., Kiedrowski, L. A., Hutchins, J. L., Hardin, A. I., Wei, Z., Hong, F., Bahcall, M., et al. (2022) · Nature · doi:10.1038/s41586-022-04451-4 · Cited by 56 · see citing works
KRAS: A Druggable Target in Colon Cancer Patients
Negri, F., Bottarelli, L., de’Angelis, G. L., & Gnetti, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084120 · Cited by 55 · see citing works
TFEB Links MYC Signaling to Epigenetic Control of Myeloid Differentiation and Acute Myeloid Leukemia
Yun, S., Vincelette, N. D., Yu, X., Watson, G. W., Fernandez, M. R., Yang, C., Hitosugi, T., Cheng, C., Freischel, A. R., Zhang, L., et al. (2020) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0029 · Cited by 50 · see citing works
Self-citationBooth, L. A., Roberts, J. L., Sander, C., Lalani, A. S., Kirkwood, J. M., Hancock, J. F., Poklepovic, A. S., & Dent, P. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1551747 · Cited by 49 · see citing works
Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors
Carvalho, P. D., Machado, A. L., Martins, F., Seruca, R., & Velho, S. (2019) · Cancers · doi:10.3390/cancers11122010 · Cited by 48 · see citing works
Targeting KRAS mutant lung cancer: light at the end of the tunnel
Drosten, M., & Barbacid, M. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13168 · Cited by 47 · see citing works
RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma
East, P., Kelly, G. P., Biswas, D., Marani, M., Hancock, D. C., Creasy, T. H., Sachsenmeier, K. F., Swanton, C., Downward, J., & Trécesson, S. D. C. (2022) · Nature Communications · doi:10.1038/s41467-022-33290-0 · Cited by 42 · see citing works
KRAS: A Promising Therapeutic Target for Cancer Treatment
Wu, H.-Z., Xiao, J., Xiao, S., & Cheng, Y. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190905164144 · Cited by 41 · see citing works
Human-correlated genetic models identify precision therapy for liver cancer
Müller, M., May, S., Hall, H., Kendall, T. J., McGarry, L., Blukacz, L., Nuciforo, S., Γεωργακοπούλου, Α., Jamieson, T., Phinichkusolchit, N., et al. (2025) · Nature · doi:10.1038/s41586-025-08585-z · Cited by 40 · see citing works
Self-citationTang, Y., Pu, X., Yuan, X., Pang, Z., Li, F., & Wang, X. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00778-4 · Cited by 37 · see citing works
Cooke, M., Kreider-Letterman, G., Baker, M. J., Zhang, S., Sullivan, N. T., Eruslanov, E. B., Abba, M. C., Goicoechea, S. M., García‐Mata, R., & Kazanietz, M. G. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109905 · Cited by 37 · see citing works
ERK Inhibitor LY3214996-Based Treatment Strategies forRAS-Driven Lung Cancer
Köhler, J., Zhao, Y., Li, J., Gokhale, P. C., Tiv, H. L., Knott, A., Wilkens, M. K., Soroko, K. M., Lin, M., Ambrogio, C., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0531 · Cited by 36 · see citing works
Targeting RAS mutants in malignancies: successes, failures, and reasons for hope
Yang, H. S., Zhou, X., Fu, D., Le, C., Wang, J., Zhou, Q., Liu, X., Yuan, Y., Ding, K., & Xiao, Q. (2022) · 癌症：英文版 · doi:10.1002/cac2.12377 · Cited by 35 · see citing works
Cancer Treatment in the Genomic Era
Doherty, G. J., Petruzzelli, M., Beddowes, E. J., Ahmad, S. S., Caldas, C., & Gilbertson, R. J. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-062917-011840 · Cited by 34 · see citing works
Karimi, N., & Moghaddam, S. J. (2023) · Cells · doi:10.3390/cells12050749 · Cited by 33 · see citing works
Cucurull, M., Notario, L., Sánchez‐Céspedes, M., Hierro, C., Estival, A., Carcereny, E., & Saigí, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.793121 · Cited by 33 · see citing works
Boch, T., Köhler, J., Janning, M., & Loges, S. (2022) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2022.0540 · Cited by 32 · see citing works
Targeting UHRF1-dependent DNA repair selectively sensitizes KRAS mutant lung cancer to chemotherapy
Tian, D., Tang, J., Geng, X., Li, Q., Wang, F., Zhao, H., Narla, G., Yao, X., & Zhang, Y. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.08.008 · Cited by 31 · see citing works
Hepatic glutamine synthetase controls N5-methylglutamine in homeostasis and cancer
Villar, V. H., Allega, M. F., Deshmukh, R. S., Ackermann, T., Nakasone, M. A., Voorde, J. V., Drake, T. M., Oetjen, J., Bloom, A., Nixon, C., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01154-9 · Cited by 28 · see citing works
Self-citationThe Nucleolus: A Central Hub for Ribosome Biogenesis and Cellular Regulatory Signals
Ponti, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094174 · Cited by 27 · see citing works
Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer
Ye, W., Lu, X., Qiao, Y., & Ou, W. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189108 · Cited by 25 · see citing works
Targeting RAS in neuroblastoma: Is it possible?
Lin, L., Miao, L., Lin, H., Cheng, J., Li, M., Zhuo, Z., & He, J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108054 · Cited by 24 · see citing works
Rosell, R., Aguilar, A., Pedraz‐Valdunciel, C., & CHAIB-OUKADOUR, I. (2021) · Nature Cancer · doi:10.1038/s43018-021-00289-3 · Cited by 23 · see citing works
Emerging RAS-directed therapies for cancer
Conroy, M. R., Cowzer, D., Kölch, W., & Duffy, A. G. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.07 · Cited by 22 · see citing works
Yang, X., Chen, Y., Zhou, Y., Wu, C., Li, Q., Wu, J., Hu, W., Zhao, W., Wei, W., Wu, C. P., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01837-y · Cited by 22 · see citing works
Stangl, C., Post, J. B., van Roosmalen, M. J., Hami, N., Verlaan-Klink, I., Vos, H. R., van Es, R. M., Koudijs, M. J., Voest, E. E., Snippert, H. J. G., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0529 · Cited by 21 · see citing works
Milton, C. K., Self, A. J., Clarke, P. A., Banerji, U., Piccioni, F., Root, D. E., & Whittaker, S. R. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-1131 · Cited by 21 · see citing works
Kim, S., Kim, N., Kang, K., Kim, W., Won, J., & Cho, J. (2019) · Cells · doi:10.3390/cells8080878 · Cited by 20 · see citing works
Liu, H., Zhao, F., Zhang, K., Zhao, J., & Wang, Y. (2021) · Food & Function · doi:10.1039/d1fo01936h · Cited by 19 · see citing works
Tsukumo, Y., Naito, M., & Suzuki, T. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229712 · Cited by 17 · see citing works
Anti-tumor activity of neratinib, a pan-HER inhibitor, in gastric adenocarcinoma cells
Hamzehlou, S., Momeny, M., Zandi, Z., Kashani, B., Yousefi, H., Dehpour, A. R., Tavakkoly‐Bazzaz, J., & Ghaffari, S. H. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172705 · Cited by 17 · see citing works
Ye, R., Yu, Y., Zhao, R., Han, Y., & Lu, S. Y. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1101443 · Cited by 16 · see citing works
Almotlak, A. A., Farooqui, M., & Siegfried, J. M. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.09.195 · Cited by 16 · see citing works
Not the comfy chair! Cancer drugs that act against multiple active sites
Booth, L. A., Poklepovic, A. S., & Dent, P. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1691526 · Cited by 16 · see citing works
iRhom2 regulates ERBB signalling to promote KRAS-driven tumour growth of lung cancer cells
Sieber, B., Lu, F., Stribbling, S. M., Grieve, A. G., Ryan, A. J., & Freeman, M. (2022) · Journal of Cell Science · doi:10.1242/jcs.259949 · Cited by 16 · see citing works
JMJD5 inhibits lung cancer progression by facilitating EGFR proteasomal degradation
Shen, J., Liu, G., Qi, H., Xiang, X., & Shao, J. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06194-0 · Cited by 15 · see citing works
Gong, K., Guo, G., Beckley, N. A., Yang, X., Zhang, Y., Gerber, D. E., Minna, J. D., Burma, S., Zhao, D., Akbay, E. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27276-7 · Cited by 15 · see citing works
Nucleolar localization of the ErbB3 receptor as a new target in glioblastoma
Tagliaferro, M., Rosa, P., Bellenchi, G. C., Bastianelli, D., Trotta, R., Tito, C., Fazi, F., Calogero, A., & Ponti, D. (2022) · BMC Molecular and Cell Biology · doi:10.1186/s12860-022-00411-y · Cited by 15 · see citing works
Synergy of EGFR and AURKA Inhibitors in <i>KRAS</i> -mutated Non–small Cell Lung Cancers
Bagnyukova, T., Egleston, B. L., Pavlov, V. A., Serebriiskii, I. G., Golemis, E. A., & Borghaei, H. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0482 · Cited by 14 · see citing works
Crosstalk with lung fibroblasts shapes the growth and therapeutic response of mesothelioma cells
Chrisochoidou, Y., Roy, R., Farahmand, P., Gonzalez, G., Doig, J., Krásný, L., Rimmer, E. F., Willis, A. E., MacFarlane, M., Huang, P. H., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06240-x · Cited by 14 · see citing works
Self-citationAlmotlak, A. A., Farooqui, M., Soloff, A. C., Siegfried, J. M., & Stabile, L. P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010081 · Cited by 14 · see citing works
KRASG12C inhibitor: combing for combination
Chakraborty, A. (2020) · Biochemical Society Transactions · doi:10.1042/bst20200473 · Cited by 14 · see citing works
Ding, K., Jiang, X., Wang, Z., Zou, L., Cui, J., Li, X., Shu, C., Li, A., & Zhou, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108794 · Cited by 12 · see citing works
Kinase signalling adaptation supports dysfunctional mitochondria in disease
Skalka, G., Tsakovska, M., & Murphy, D. J. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1354682 · Cited by 12 · see citing works
Self-citationNeidler, S., Kruspig, B., Hewit, K. D., Monteverde, T., Gyurászová, K., Braun, A., Clark, W. A., James, D. T., Hedley, A., Nieswandt, B., et al. (2019) · Cancers · doi:10.3390/cancers11050600 · Cited by 11 · see citing works
Self-citationKale, R. R., Samant, C., Nandakumar, K., Pai, K. S. R., & Bhonde, M. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151688 · Cited by 10 · see citing works
Hepatic zonation determines tumorigenic potential of mutant β-catenin
Raven, A., Gilroy, K. L., Jin, H., Waldron, J. A., Leslie, H., Munro, J., Hall, H., Ridgway, R. A., Ford, C. A., Gulhan, D., et al. (2025) · Nature · doi:10.1038/s41586-025-09733-1 · Cited by 10 · see citing works
Self-citationTrisomy 8 Defines a Distinct Subtype of Myeloproliferative Neoplasms Driven by the MYC–Alarmin Axis
Vincelette, N. D., Yu, X., Kuykendall, A. T., Moon, J., Su, S., Cheng, C., Sammut, R., Razabdouski, T. N., Nguyen, H. V., Eksioglu, E. A., et al. (2024) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0210 · Cited by 10 · see citing works
Self-citationFunctional diagnostics using fresh uncultured lung tumor cells to guide personalized treatments
Talwelkar, S. S., Mäyränpää, M. I., Søraas, L., Potdar, S., Bao, J., Hemmes, A., Linnavirta, N., Lømo, J., Räsänen, J. V., Knuuttila, A., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100373 · Cited by 10 · see citing works
Maturation, developmental site, and pathology dictate murine neutrophil functionPreprint
Mackey, J. B. G., McFarlane, A. J., Jamieson, T. J., Jackstadt, R., Iraolagoitia, X. L. R., Secklehner, J., Cortés-Lavaud, X., Fercoq, F., Clarke, W., Hedley, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.21.453108 · Cited by 10 · see citing works
Self-citationAssessment of the WAP-Myc mouse mammary tumor model for spontaneous metastasis
Utz, B., Turpin, R., Lampe, J. W., Pouwels, J., & Klefström, J. T. (2020) · Scientific Reports · doi:10.1038/s41598-020-75411-z · Cited by 9 · see citing works
Statins mediate anti- and pro-tumourigenic functions by remodelling the tumour microenvironment
Kamata, T., Aldujaily, E., Alhamad, S., So, T. Y., Margaritaki, O., Giblett, S. M., Pringle, J. H., Quesne, J. P. C. L., & Pritchard, C. A. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.049148 · Cited by 9 · see citing works
Yan, Y., Wang, M., Gan, X., Wang, X., Fu, C., Li, Y., Chen, N., Lv, P., & Zhang, Y. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1083581 · Cited by 8 · see citing works
Prevention of Akt phosphorylation is a key to targeting cancer stem-like cells by mTOR inhibition
Matsubara, S., Tsukasa, K., Kuwahata, T., & Takao, S. (2020) · Human Cell · doi:10.1007/s13577-020-00416-9 · Cited by 8 · see citing works
If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for KRAS-Mutant Lung Cancer
Köhler, J., & Janne, P. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063025 · Cited by 7 · see citing works
Piha-Paul, S. A., Tseng, C., Tran, H. T., Gao, M., Karp, D. D., Subbiah, V., Tsimberidou, A. M., Kawedia, J. D., Fu, S., Pant, S., et al. (2023) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-023-04545-4 · Cited by 7 · see citing works
Talwelkar, S. S., Nagaraj, A. S., Devlin, J. R., Hemmes, A., Potdar, S., Kiss, E. A., Saharinen, P., Salmenkivi, K., Mäyränpää, M. I., Wennerberg, K., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0573 · Cited by 7 · see citing works
D-mannose induces TFE3-dependent lysosomal degradation of EGFR and inhibits the progression of NSCLC
Sun, X., Dai, Y., He, J., Li, H., Yang, X., Dong, W., Xie, X., Wang, M., Xu, Y., & Lv, L. (2023) · Oncogene · doi:10.1038/s41388-023-02856-7 · Cited by 6 · see citing works
Recent advances in targeted degradation in the RAS pathway
Ge, Z., Fan, Z., He, W., Zhou, G., Zhou, Y., Zheng, M., & Zhang, S. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2476387 · Cited by 5 · see citing works
Hua, W.-J., Hwang, W., Yeh, H. H., Lin, Z., Hsu, W.-H., & Lin, T. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.129291 · Cited by 5 · see citing works
Nucleophosmin supports WNT-driven hyperproliferation and tumor initiation
Kanellos, G., Giacomelli, C., Raven, A., Vlahov, N., Jin, H., Herviou, P., Malla, S. B., Nasreddin, N., Centeno, P. P., Alexandrou, C., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02408-7 · Cited by 4 · see citing works
Self-citationZhou, H., Zhao, H., Hou, X., Wang, Y., He, Z., Li, Y., Ma, Y., Zhao, Y.-H., Huang, Y., Chen, L., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-01929 · Cited by 4 · see citing works
JeanRichard, P., Ananthanarayan, A., Wu, L., Jazaeri, A., Bachmann, D., & Kaufmann, T. (2026) · Cell Death and Differentiation · doi:10.1038/s41418-026-01666-0 · Cited by 3 · see citing works
Olmo-González, D., Zhou, M., Oliveira, N. G., Zhou, F., Yan, F., González, J., València-Clua, K., Molina‐Vila, M. Á., Bertrán-Alamillo, J., Giménez-Capitán, A. A., et al. (2026) · Cell Death Discovery · doi:10.1038/s41420-026-02998-z · Cited by 3 · see citing works
Post, J. B., Hami, N., Lohuis, J. O., van de Ven, M., de Korte‐Grimmerink, R., Stangl, C., Stelloo, E., Verlaan-Klink, I., van Rheenen, J., & Snippert, H. J. G. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/860122 · Cited by 3 · see citing works
A tyrosine kinase protein interaction map reveals targetable EGFR network oncogenesis in lung cancerPreprint
Kaushik, S., Haderk, F., Zhao, X., Hu, H., Shah, K. N., Jang, G. Μ., Olivas, V. R., Nanjo, S., Jascur, J., Masto, V. B., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.02.185173 · Cited by 3 · see citing works
Jasim, S. A., Omear, H. A., & AL-Marzoqi, A. H. (2021) · Gene Reports · doi:10.1016/j.genrep.2021.101436 · Cited by 2 · see citing works
Romero, D. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0068-1 · Cited by 2 · see citing works
Breaking bad family ties: Pan-ERBB blockers inhibit KRAS driven lung tumorigenesis
Moll, H. P., & Casanova, E. (2018) · Molecular & Cellular Oncology · doi:10.1080/23723556.2018.1513724 · Cited by 2 · see citing works
eIF4A1 is essential for reprogramming the translational landscape of Wnt-driven colorectal cancersPreprint
Waldron, J. A., Kanellos, G., Smith, R. C. L., Knight, J. R. P., Munro, J., Alexandrou, C., Vlahov, N., Pardo, L., Moore, M. H., Gillen, S. L., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.10.566546 · Cited by 2 · see citing works
Self-citationÖzakıncı, H., Desai, B., Kalos, D., Chen, D., Henry, M., Solanki, H. S., Boyle, T. A., Bittar, H. E. T., Nazario, G. S., Haura, E. B., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.17.628751 · Cited by 2 · see citing works
Non-canonical EGFR signaling promotes MAPK-dependent extrusion of epithelial cells
Molina, P., Daniel, M., Hoang, T., Wang, J., & Macara, I. G. (2025) · Journal of Cell Science · doi:10.1242/jcs.264173 · Cited by 1 · see citing works
The repressor Capicua is a barrier to lung tumor development driven by Kras/Trp53 mutations
Ballesteros-González, I., Hernández-Navas, I., Brehey, O., Lechuga, C. G., Salmón, M., Scotece, M., Velasco-Vicente, R., Flores-Gómez, A. A., Cebriá, A., Simón-Carrasco, L., et al. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00326-z · Cited by 1 · see citing works
KRAS mutated lung adenocarcinoma responds to pan-ERBB and Aurora kinase inhibitors
Uras, I. Z., Trkulja, M. V., Salama, A. K. A. A., Horvath, J., Asnani, K., Trenk, C., Kubicek, S., Bilban, M., Moll, H. P., & Casanova, E. (2026) · npj Precision Oncology · doi:10.1038/s41698-025-01242-8 · Cited by 1 · see citing works
Iraolagoitia, X. L. R., McFarlane, A. J., Laing, S., Corbyn, R., Arnott, L. W. G., Fercoq, F., McGarry, L., Secklehner, J., Donatis, M. D., Mackey, J. B. G., et al. (2026) · Science Advances · doi:10.1126/sciadv.adu8802 · Cited by 1 · see citing works
Self-citationDart, A. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0044-1 · Cited by 1 · see citing works
ERBB signalling contributes to immune evasion in KRAS-driven lung adenocarcinomaPreprint
Laing, S., Kruspig, B., Shaw, R., Officer-Jones, L., Edwards, S. C., McKinven, D., Hsieh, Y.-C., Powley, I. R., Brady, N., Pennie, R. L., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.24.550274 · Cited by 1 · see citing works
Self-citationLatent Regulatory Programs Generate Synthetic T Cell States with Enhanced Therapeutic PotentialPreprint
Pratt, B. M., Mullins, G. N., Brown, N. J., Green, W. D., Modliszewski, J. L., Xie, F., van Rooyen, L., Zhabotynsky, V., Jambor, A. N., Cannon, G. H., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.07.698190 · Cited by 1 · see citing works
Rodrigues, F. S. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.46.2018.tde-26112018-080111
Development of an adenosquamous carcinoma histopathology – selective lung metastasis model
Lähdeniemi, I. A. K., Devlin, J. R., Nagaraj, A. S., Talwelkar, S. S., Bao, J., Linnavirta, N., Şeref, C., Kiss, E. A., Hemmes, A., & Verschuren, E. W. (2022) · Biology Open · doi:10.1242/bio.059623
Knight, J. R. P., Alexandrou, C., Skalka, G., Vlahov, N., Pennel, K. A. F., Officer, L., Teodòsio, A., Kanellos, G., Gay, D. M., May-Wilson, S., et al. (2023) · doi:10.1158/2159-8290.c.6549409
- Authors
- Kruspig, B., Monteverde, T., Neidler, S., Hock, A., Kerr, E., Nixon, C., Clark, W., Hedley, A., Laing, S., Coffelt, S. B., Le Quesne, J., Dick, C., Vousden, K. H., Martins, C. P., & Murphy, D. J.
- Affiliations
- University of Glasgow (GB)
- Cancer Research UK Scotland Institute (GB)
- MRC Cancer Unit (GB)
- MRC Toxicology Unit, Leicester LE1 7HB, UK.
- National Health Service (GB)
- Corresponding author
- Kruspig, Björn
- Monteverde, Tiziana
- Murphy, Daniel J.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2018-06-20
- Volume
- 10
- Issue
- 446
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC6881183
- OpenAlex
- W2809593667
- Cited by
- 111
- References
- 47
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 8 · 2023: 12 · 2022: 14 · 2021: 19 · 2020: 16 · 2019: 15 · 2018: 6
- FWCI
- 10.54
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Science Translational Medicine (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Funders
- Medical Research Council (5TS30)
- British Lung Foundation (APHD13-5, CSOBLF RG16-2)
- European Commission (CIG 618448, 705190 “NuSiCC”)
- Deutsche Krebshilfe (109220)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- KRAS mutation, lung cancer, lung carcinogenesis, Ras signaling, MEK inhibition, combination therapy, tumor progression, cell proliferation
- MeSH terms
- Adenocarcinoma of Lung, Animals, Humans, Lung Neoplasms, Mutation, Phosphorylation, Signal Transduction, Gene Expression Regulation, Neoplastic, Survival Analysis, Proto-Oncogene Proteins p21(ras), Apoptosis, Disease Progression, Mitogen-Activated Protein Kinase Kinases, Cell Line, Tumor, Extracellular Signal-Regulated MAP Kinases, Cell Proliferation, Mice, Gene Regulatory Networks, Carcinogenesis, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
